If you have time for an espresso
- Honda’s reset is now impossible to ignore. Ars reports Honda is absorbing more than $9 billion in EV-related write-downs, retooling U.S. factories for hybrids, and redirecting battery capacity toward hybrid traction batteries instead of the all-EV path it had mapped out earlier.
https://arstechnica.com/cars/2026/05/honda-shows-off-new-hybrids-for-america-as-it-absorbs-9-billion-ev-loss/ - U.S. factory output got a real lift from autos in April. The Federal Reserve said industrial production rose 0.7% and manufacturing output rose 0.6%, with motor vehicles and parts doing a lot of the work even as the broader manufacturing picture stays mixed.
https://www.federalreserve.gov/releases/g17/current/default.htm - Waymo’s flooded-road recall is a sharp reminder that software-defined vehicles still live or die on edge-case validation. NHTSA says 3,791 Waymo automated driving systems are affected by software that may allow a vehicle to slow and then continue into standing water on higher-speed roads.
https://static.nhtsa.gov/odi/rcl/2026/RCAK-26E026-9973.pdf - Medtech got a notable regulatory milestone from Aurie. The company says FDA granted De Novo authorization for what it calls the first reusable intermittent urinary catheter system, a signal that cost, sustainability, and user-centered redesign are starting to matter more in device categories long dominated by disposables.
https://www.prnewswire.com/news-releases/aurie-receives-fda-de-novo-grant-for-first-automated-safely-reusable-intermittent-urinary-catheter-system-302767331.html
If you’re sipping a latte
- Tesla has ended Model S and Model X production. Car and Driver frames it as the close of two vehicles that helped mainstream performance EVs, but it also underlines how quickly even iconic nameplates can get pushed aside when portfolios, factory priorities, and software bets shift.
https://www.caranddriver.com/news/a71284161/tesla-model-s-x-production-end/ - Mazda is making the same kind of pivot, just from a smaller base. Jalopnik reports the company is delaying its first dedicated EV to 2029, cutting EV investment, and leaning harder into hybrids and partner-sourced electrified products.
https://www.jalopnik.com/2170750/mazda-follows-crowd-ev-in-favor-hybrids/ - Medtronic plans to wind down its Santa Rosa, California site over roughly two years. MedTech Dive says the move comes as the company consolidates parts of its cardiovascular business, which is the kind of portfolio reshaping that tends to ripple into sourcing, tooling, transfer work, and supplier qualification.
https://www.medtechdive.com/news/medtronic-to-close-california-site-amid-restructuring/819852/ - Epineuron picked up FDA 510(k) clearance for its Evala nerve stimulator. It’s a smaller story than the biggest medtech headlines, but it’s another useful sign that neurotech and precision intervention platforms are still moving through the U.S. regulatory channel.
https://www.massdevice.com/epineuron-wins-fda-clearance-nerve-stimulator/ - A very different kind of automotive signal came out of Oklahoma City: production assets from Canoo and Arrival are heading to auction. For manufacturers willing to move fast, this is a real secondary-market opportunity to pick up battery, test, automation, and EV assembly equipment without greenfield lead times.
https://www.prnewswire.com/news-releases/assetbuilt-to-auction-former-assets-of-canoo-and-arrival-in-major-global-ev-manufacturing-event-302769245.html
If you’ve got a venti anything
- The EV market isn’t “dead”; it’s being re-sorted around hybrids, capital discipline, and regional pragmatism. Honda’s losses and Mazda’s delay show the same thing from two angles: automakers still want electrification, but many are retreating from all-EV timelines in favor of architectures that ask less of battery supply chains and less of consumers.
https://arstechnica.com/cars/2026/05/honda-shows-off-new-hybrids-for-america-as-it-absorbs-9-billion-ev-loss/ - Medtech manufacturing keeps consolidating around scale, resilience, and breadth of process capability. Medical Design & Outsourcing reports Tecomet and Orchid have completed their merger, creating a larger platform across machining, additive, forging, casting, finishing, and packaging. For OEMs, that is attractive because it simplifies supplier management; for smaller specialist suppliers, it raises the bar on where they need to be truly differentiated.
https://www.medicaldesignandoutsourcing.com/tecomet-and-orchid-complete-merger-form-global-platform/ - Factory AI is getting more operational and less theoretical. Tech Briefs’ look at Siemens’ Eigen Engineering Agent is worth reading because it focuses on actual engineering tasks like PLC coding, HMI generation, device configuration, and standards compliance, not just generic “AI for manufacturing” claims. For automotive, battery, and regulated manufacturing teams, the interesting question is no longer whether AI will show up on the plant floor, but where it can shorten launch cycles without creating new quality or traceability problems.
https://www.techbriefs.com/component/content/article/55175-agentic-ai-moves-from-hype-to-reality-in-automation-engineering
What it means for customers
This week’s pattern is pretty clear: customers are being pushed toward platforms and suppliers that can handle change without drama. In auto, that means hybrid-ready thinking, tighter software validation, and faster reuse of manufacturing assets; in medtech, it means regulatory discipline plus scalable, resilient production partners. For the kinds of companies TKD2 cares about, the opportunity is in helping OEMs move faster on product, process, and localization decisions while reducing launch, quality, and supply-chain risk.
